top of page

Emily Dworkin

PharmD, BCOP




PharmD: University of Iowa

Residency Training

PGY1: University of Wisconsin Health
PGY2 Oncology/Hematology: University of Wisconsin Health

Emily Dworkin

Practice Interests

Acute leukemias, treatment of leukemia in the adolescent and young adult population, quality improvement and pharmacy practice advancement

Professional Affiliation

  • Hematology/Oncology Pharmacy Association (HOPA)

  • American Society of Health-System Pharmacists (ASHP)

Recent Publications

  • Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO State of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(11):725-733.

  • Patel AA, Heng J, Dworkin E, Monick S, Derman B, et al. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. eJHaem. Published online June 2021.

  • Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152-159.

  • Dworkin E, Hager D. Taking the fear out of feedback: models for success. J Pharm Soc Wis.2016;19(2):22-25.

Academic and/or National Presentations

  • Optimal intensive induction for older adults with newly diagnosed acute myeloid leukemia. Presented at the Hematology/Oncology Pharmacy Association Annual Conference. Boston, MA. April 2022

  • Checkpoint inhibitors in hematologic malignancies. Recorded Lecture for The Hematology/Oncology Pharmacy Association 2021 BCOP Oncology Pharmacy Updates

  • Advances in targeted therapy for AML: Practical management of BCL-2 inhibitors. Abbvie Sponsored Symposium. Presented at The Hematology/Oncology Pharmacy Association Annual Conference. [Virtual] April 2021

Current Research

  • Off label prescribing of novel agents in acute myeloid leukemia, with Jordan Baur, PharmD

  • The impact of a pharmacist driven protocol for management of 6MP and oral MTX during AML maintenance therapy with Kaitlin Kelly, PharmD, BCOP

bottom of page